TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint InhibitorsScott T. Tagawa, Petros Grivas, Arjun Vasant Balar et al.|Journal of Clinical Oncology|2021Cited by 530
COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trialsAakash Desai, Vivek Subbiah, Justin F. Gainor et al.|Nature Reviews Clinical Oncology|2021Cited by 140
CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell CarcinomaSumanta K. Pal, Samer A. Srour, Nizar M. Tannir et al.|Cancer Discovery|2024Cited by 137
Clinical Activity and Safety of Cabozantinib for Brain Metastases in Patients With Renal Cell CarcinomaLaure Hirsch, Toni K. Choueiri, Nieves Martínez Chanzá et al.|JAMA Oncology|2021Cited by 95
Parallel (Randomized) Phase II Evaluation of Tivantinib (ARQ197) and Tivantinib in Combination with Erlotinib in Papillary Renal Cell Carcinoma: SWOG S1107Przemyslaw Twardowski, Primo N. Lara, Catherine M. Tangen et al.|Kidney Cancer|2017Cited by 41